Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over time: A follow-up of patients included in the childhood cancer registry of the Rhône-Alpes region in France (ARCERRA)

2008 ◽  
Vol 50 (6) ◽  
pp. 1213-1220 ◽  
Author(s):  
Fernand Freycon ◽  
Béatrice Trombert-Paviot ◽  
Léonie Casagranda ◽  
Yves Bertrand ◽  
Dominique Plantaz ◽  
...  
Keyword(s):  
Childhood Cancer ◽  
Cancer Registry ◽  
Over Time

scholarly journals Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinics

2013 ◽  
Vol 168 (3) ◽  
pp. 465-472 ◽  
Author(s):  
E Brignardello ◽  
F Felicetti ◽  
A Castiglione ◽  
P Chiabotto ◽  
A Corrias ◽  
...  
Keyword(s):  
Cancer Survivors ◽  
Childhood Cancer ◽  
Cancer Diagnosis ◽  
Late Effects ◽  
Cumulative Incidence ◽  
Endocrine Disease ◽  
Male Sex ◽  
Monitoring Protocols ◽  
Over Time

BackgroundSurvival rates among childhood cancer survivors (CCS) have enormously increased in the last 40 years. However, this improvement has been achieved at the expense of serious late effects that frequently involve the endocrine system.AimTo evaluate the cumulative incidence of endocrine diseases in a cohort of long-term CCS.Materials and methodsWe analyzed the clinical data of 310 adults, followed for a median time of 16.0 years after the first cancer diagnosis. The monitoring protocols applied to each patient were personalized on the basis of cancer diagnosis and previous treatments, according to the Children's Oncology Group guidelines.ResultsThe cumulative incidence of endocrine late effects steadily increased over time. At the last follow-up visit available, 48.46% of females and 62.78% of males were affected by at least one endocrine disease. The most common disorders were gonadal dysfunction, primary hypothyroidism, and GH deficiency (GHD). The main risk factors for endocrine disease were male sex (hazard ratio (HR)=1.45, 95% confidence interval (95% CI) 1.05–1.99), radiotherapy (HR=1.91, 95% CI 1.28–2.84), hematopoietic stem cells transplantation (HR=3.11, 95% CI 2.23–4.34), and older age at cancer diagnosis (HR=1.89, 95% CI 1.25–2.85). Male sex was associated with a higher risk of gonadal disorders, whereas radiotherapy specifically increased the risk of GHD and thyroid dysfunction.ConclusionsEndocrine disorders among CCS have a high prevalence and increase over time. Thus, endocrinologists need to cope with an increasing demand for health care in a field that is still little developed and that, in perspective, could also be extended to some selected types of adult cancer survivors.

scholarly journals Indicators of Data Quality at the Cancer Registry Zurich and Zug in Switzerland

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Miriam Wanner ◽  
Katarina L. Matthes ◽  
Dimitri Korol ◽  
Silvia Dehler ◽  
Sabine Rohrmann
Keyword(s):  
Data Quality ◽  
Childhood Cancer ◽  
Cancer Registry ◽  
Incidence Rates ◽  
Cancer Registration ◽  
Reference Ranges ◽  
Comprehensive Overview ◽  
Non Melanoma Skin Cancer ◽  
The Stability ◽  
Over Time

Data quality is an important issue in cancer registration. This paper provides a comprehensive overview of the four main data quality indicators (comparability, validity, timeliness, and completeness) for the Cancer Registry Zurich and Zug (Switzerland). We extracted all malignant cancer cases (excluding non-melanoma skin cancer) diagnosed between 1980 and 2014 in the canton of Zurich. Methods included the proportion of morphologically verified cases (MV%), the proportion of DCN and DCO cases (2009–2014), cases with primary site uncertain (PSU%), the stability of incidence rates over time, age-specific incidence rates for childhood cancer, and mortality:incidence (MI) ratios. The DCO rate decreased from 6.4% in 1997 to 0.8% in 2014 and was <5% since 2000. MV% was 95.5% in 2014. PSU% was <3% over the whole period. The incidence rate of all tumours increased over time with site-specific fluctuations. The overall M:I ratio decreased from 0.58 in 1980 to 0.37 in 2014. Overall, data quality of the Cancer Registry Zurich and Zug was acceptable according to the methods presented in this review. Most indicators improved over time with low DCO rates, high MV%, low PSU%, relatively low M:I ratios and age-specific incidence of childhood cancer within reference ranges.

scholarly journals Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis

2020 ◽  
Author(s):  
Ryan N Hansen ◽  
Yiduo Zhang ◽  
Brian Seal ◽  
Kellie Ryan ◽  
Candice Yong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Registry ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Unresectable Stage ◽  
Stage Iii Nsclc ◽  
Over Time

Abstract Background: To evaluate the value of new therapies for non-small cell lung cancer (NSCLC), it is necessary to understand overall survival (OS) rates associated with previous standard therapies and how these rates have evolved over time. Methods: We retrospectively analyzed data from patients enrolled in the Surveillance, Epidemiology, and End Results (SEER) cancer registry. Adults with unresectable, stage III NSCLC treated with chemoradiotherapy were grouped by diagnosis year (2000–2002; 2003–2005; 2006–2008; 2009–2011; 2012–2013). The primary endpoint was OS (data cut-off, December 31, 2014), estimated using the Kaplan–Meier estimator. Temporal survival-trend significance was tested using a two-sided log-rank trend test. Results: Of 12,865 eligible patients, 59.1% were male, 59.9% had stage IIIB disease, and 62.7% had non-squamous histology. Median age at diagnosis was 67 years. Overall, 10,899 (84.7%) patients died and 1,966 (15.3%) were censored/lost to follow-up. Median follow-up (95% confidence interval [CI]) was 80 (77–82) months; median OS (95% CI) was 15 (15–16) months; 1- and 3-year survival probabilities (95% CI) were 57.7% (56.9–58.6) and 24.1% (23.3–24.8), respectively. Stratification by diagnosis year showed consistent improvements in survival over time ( p < 0.0001 for trend). Median OS was 12, 14, 15, 18, and 19 months in successive cohorts. Conclusions: OS in patients diagnosed with unresectable, stage III NSCLC between 2003 and 2013 was consistent with that from clinical studies of sequential/concurrent chemoradiotherapy. Despite improvement over time, median OS was <2 years and mortality remained high during the first year post-diagnosis.

Changes over Time: A Study of Family Bereavement following Childhood Cancer

1994 ◽  
Vol 10 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Ida M. Martinson ◽  
Sandra G. Mcclowry ◽  
Betty Davies ◽  
E. J. Kuhlenkamp
Keyword(s):  
Marital Status ◽  
Childhood Cancer ◽  
Family System ◽  
Family Members ◽  
Follow Up Study ◽  
The Family ◽  
Loss Of A Child ◽  
Changes Over Time ◽  
Over Time

A longitudinal follow-up study which examined changes in 48 families over time (7-9 years) following a death of a child with cancer was conducted. The loss of a child required individual reorganization and adjustments within the family system. Changes in marital status and/or the addition of other children required adjustment in the relationships of family members. Some of the changes were developmental in nature while others, according to the informants, were directly related to the death of the child.

scholarly journals Importance of the National Childhood Cancer Registry in the field of paediatric oncology care

2014 ◽  
Vol 155 (19) ◽  
pp. 732-739 ◽  
Author(s):  
Miklós Garami ◽  
Dezső Schuler ◽  
Zsuzsanna Jakab
Keyword(s):  
Childhood Cancer ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Paediatric Oncology ◽  
Treatment Modalities ◽  
Cancer Registration ◽  
Childhood Cancers ◽  
Paediatric Cancer ◽  
Oncology Care

National Childhood Cancer Registry has been operated since 1971 by the Hungarian Paediatric Oncology Network. This Registry collects data on epidemiology, treatment modalities and effectiveness, as well as late follow-up of childhood cancers. An internet-based paediatric cancer registration and communication system for the Hungarian Paediatric Oncology Network has been introduced in April, 2010. The National Childhood Cancer Registry contains data of all paediatric cancer patients (0–18 yrs) who have insurance covered by the Hungarian Social Security Card. Creation (1971) and operation of the National Childhood Cancer Registry have been very important steps in the field of childhood oncology to evaluate the efficiency of paediatric oncology treatments as well as maximize return on medical investment. Orv. Hetil., 2014, 155(19), 732–739.

scholarly journals Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis

2020 ◽  
Author(s):  
Ryan N Hansen ◽  
Yiduo Zhang ◽  
Brian Seal ◽  
Kellie Ryan ◽  
Candice Yong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Registry ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Unresectable Stage ◽  
Stage Iii Nsclc ◽  
Over Time

Abstract Background: To evaluate the value of new therapies for non-small cell lung cancer (NSCLC), it is necessary to understand overall survival (OS) rates associated with previous standard therapies and how these rates have evolved over time. Methods: We retrospectively analyzed data from patients enrolled in the Surveillance, Epidemiology, and End Results (SEER) cancer registry. Adults with unresectable, stage III NSCLC treated with chemoradiotherapy were grouped by diagnosis year (2000–2002; 2003–2005; 2006–2008; 2009–2011; 2012–2013). The primary endpoint was OS (data cut-off, December 31, 2014), estimated using the Kaplan–Meier estimator. Temporal survival-trend significance was tested using a two-sided log-rank trend test. Results: Of 12,865 eligible patients, 59.1% were male, 59.9% had stage IIIB disease, and 62.7% had non-squamous histology. Median age at diagnosis was 67 years. Overall, 10,899 (84.7%) patients died and 1,966 (15.3%) were censored/lost to follow-up. Median follow-up (95% confidence interval [CI]) was 80 (77–82) months; median OS (95% CI) was 15 (15–16) months; 1- and 3-year survival probabilities (95% CI) were 57.7% (56.9–58.6) and 24.1% (23.3–24.8), respectively. Stratification by diagnosis year showed consistent improvements in survival over time ( p < 0.0001 for trend). Median OS was 12, 14, 15, 18, and 19 months in successive cohorts. Conclusions: OS in patients diagnosed with unresectable, stage III NSCLC between 2003 and 2013 was consistent with that from clinical studies of sequential/concurrent chemoradiotherapy. Despite improvement over time, median OS was <2 years and mortality remained high during the first year post-diagnosis.

scholarly journals Change in Pain Status and Subsequent Opioid and Marijuana Use Among Long-Term Adult Survivors of Childhood Cancer

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
I-Chan Huang ◽  
Nicole M Alberts ◽  
Merrion G Buckley ◽  
Zhenghong Li ◽  
Matthew J Ehrhardt ◽  
...  
Keyword(s):  
Childhood Cancer ◽  
Marijuana Use ◽  
Adult Survivors ◽  
Opioid Use ◽  
Status Change ◽  
Pain Status ◽  
Survivors Of Childhood Cancer ◽  
Over Time

Abstract We evaluated pain status change and associations with subsequent opioid/marijuana use among 1208 adult survivors of childhood cancer. Pain status and opioid/marijuana were self-reported at baseline and follow-up evaluation (mean interval = 4.2 years). Over time, 18.7% of survivors endorsed persistent/increasing significant pain; 4.8% and 9.0% reported having used opioids and marijuana at follow-up. Persistent/increased (vs none/decreased) pain, persistent/increased (vs none/decreased) anxiety, and lack of health insurance increased odds of subsequent opioid use by 7.69-fold (95% confidence interval [CI] = 3.71 to 15.95), 2.55-fold (95% CI = 1.04 to 6.24), and 2.50-fold (95% CI = 1.07 to 5.82), respectively. Persistent/increased (vs none/decreased) depression increased odds of subsequent marijuana use by 2.64-fold (95% CI = 1.10 to 6.33).

scholarly journals Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis

2020 ◽  
Author(s):  
Ryan N Hansen ◽  
Yiduo Zhang ◽  
Brian Seal ◽  
Kellie Ryan ◽  
Candice Yong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Registry ◽  
Small Cell ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Unresectable Stage ◽  
Stage Iii Nsclc ◽  
Over Time

Abstract Background: To evaluate the value of new therapies for non-small cell lung cancer (NSCLC), it is necessary to understand overall survival (OS) rates associated with previous standard therapies and how these rates have evolved over time. Methods: We retrospectively analyzed data from patients enrolled in the Surveillance, Epidemiology, and End Results (SEER) cancer registry. Adults with unresectable, stage III NSCLC treated with chemoradiotherapy were grouped by diagnosis year (2000–2002; 2003–2005; 2006–2008; 2009–2011; 2012–2013). The primary endpoint was OS (data cut-off, December 31, 2014), estimated using the Kaplan–Meier estimator. Temporal survival-trend significance was tested using a two-sided log-rank trend test. Results: Of 12,865 eligible patients, 59.1% were male, 59.9% had stage IIIB disease, and 62.7% had non-squamous histology. Median age at diagnosis was 67 years. Overall, 10,899 (84.7%) patients died and 1,966 (15.3%) were censored/lost to follow-up. Median follow-up (95% confidence interval [CI]) was 80 (77–82) months; median OS (95% CI) was 15 (15–16) months; 1- and 3-year survival probabilities (95% CI) were 57.7% (56.9–58.6) and 24.1% (23.3–24.8), respectively. Stratification by diagnosis year showed consistent improvements in survival over time ( p < 0.0001 for trend). Median OS was 12, 14, 15, 18, and 19 months in successive cohorts. Conclusions: OS in patients diagnosed with unresectable, stage III NSCLC between 2003 and 2013 was consistent with that from clinical studies of sequential/concurrent chemoradiotherapy. Despite improvement over time, median OS was <2 years and mortality remained high during the first year post-diagnosis.

Sign in / Sign up

Export Citation Format

Share Document